Physician profile
Rachelle Megan Salunga
NPI 1801369251
$4,463.66
in general payments reported to CMS, 2019-2025
40 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Medical-Surgical (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,439 · 2022: $1,130 · 2023: $690 · 2024: $19.31 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $690.87 | 2021-2023 | Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $278.09 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $255.49 | 2021-2022 | |
| Astellas Pharma US INC | $245.50 | 2021-2023 | Xtandi, Padcev |
| Amgen INC. | $232.33 | 2021-2022 | |
| Janssen Biotech, INC. | $231.70 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $225.86 | 2021-2022 | |
| Daiichi Sankyo INC. | $172.89 | 2021-2023 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $164.51 | 2021-2022 | |
| Seagen INC. | $139.81 | 2021 | |
| Incyte Corporation | $127.05 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $125.91 | 2025 | Libtayo |
| Novo Nordisk INC | $123.79 | 2023 | |
| Karyopharm Therapeutics INC. | $121.87 | 2021 | |
| Pfizer INC. | $106.14 | 2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101.51 | 2023-2025 | |
| Lilly USA, LLC | $93.02 | 2021-2022 | |
| Celgene Corporation | $90.92 | 2021-2022 | |
| Taiho Oncology, INC. | $80.48 | 2021 | |
| Myovant Sciences INC. | $77.39 | 2021 | |
| Aveo Pharmaceuticals, INC. | $75.27 | 2022 | |
| Genzyme Corporation | $74.98 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $73.85 | 2021 | |
| Emd Serono, INC. | $58.85 | 2021 | |
| Glaxosmithkline, LLC. | $55.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.17 | 2021 | |
| Genentech USA, INC. | $45.73 | 2021-2022 | |
| Puma Biotechnology, INC. | $39.82 | 2021-2022 | |
| Dova Pharmaceuticals | $34.95 | 2021 | |
| Dendreon Pharmaceuticals LLC | $32.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.20 | 2021 | |
| Blueprint Medicines Corporation | $29.15 | 2022 | |
| Eusa Pharma (US) LLC | $28.31 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $27.82 | 2021 | |
| Coherus Oncology, INC. | $23.30 | 2022 | |
| Acrotech Biopharma INC. | $22.47 | 2021 | |
| Exelixis INC. | $20.83 | 2021 | |
| Rigel Pharmaceuticals, INC. | $19.52 | 2021 | |
| Eisai INC. | $19.35 | 2021 | |
| Secura Bio, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachelle Salunga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.